External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer

Oncologist

Volumn 20, Issue 3, 2015, Pages 257-262

  Tack, Veronique ^a   Ligtenberg, Marjolijn J L ^b   Tembuyser, Lien ^a   Normanno, Nicola ^c   Borght, Sara Vander ^d   van Krieken, Han J ^b   Dequeker, Elisabeth M C ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Biological markers; Colorectal neoplasms; Patient safety; Quality assurance

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN SERINE THREONINE KINASE; CODON; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ARTICLE; COLORECTAL CANCER; DNA EXTRACTION; GENE MUTATION; GENOTYPE; HUMAN; LABORATORY DIAGNOSIS; ONCOGENE N RAS; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CODON; COLORECTAL NEOPLASMS; EXON; GENETICS; GENOTYPING TECHNIQUE; GOOD LABORATORY PRACTICE; HEALTH CARE QUALITY; HOSPITAL LABORATORY; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; STANDARDS;

BIOMARKERS, TUMOR; CODON; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EXONS; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; LABORATORIES, HOSPITAL; LABORATORY PROFICIENCY TESTING; PATIENT SELECTION; PROTO-ONCOGENE PROTEINS; QUALITY ASSURANCE, HEALTH CARE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84925441204     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0382     Document Type: Article

References (23)

1. Heinemann V, Douillard JY, Ducreux M et al. Targeted therapy in metastatic colorectal cancer -an example of personalised medicine in action. Cancer Treat Rev 2013;39:592-601.
2. Erbitux(cetuximab) [European Public Assessment Report]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000558/WC500029111.pdf. Accessed September 25,2014.
3. Vectibix (panitumumab) [European Public Assessment Report]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000741/WC500047704.pdf. Accessed September 25,2014.
4. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369: 1023-1034.
5. Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 2011; 22:1535-1546.
6. Cathomas G. PIK3CA in colorectal cancer. Front Oncol 2014;4:35.
7. Peeters M, Price TJ, Cervantes A et al. Randomized phase III study of panitumumab with fluoro-uracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-4713.
8. Peeters M, Oliner KS, Parker A et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013;19:1902-1912.
9. Colon external quality assessment scheme. Available at http://kras.eqascheme.org. Accessed September 25, 2014.
10. Van Krieken JH, Normanno N, Blackhall F, et al. Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch 2013;462:27-37.
11. ISO. IEC 17043:2010 Conformity assessment-general requirements for proficiency testing. Geneva, Switzerland: International Organization for Standardization, 2010.
12. Bellon E, Ligtenberg MJ, Tejpar S et al. External quality assessment for KRAS testing is needed: Setup of a European program and report of the first joined regional quality assessment rounds. The Oncologist 2011;16:467-478.
13. Dequeker E, Ligtenberg MJ, Vander Borght S et al. Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: Development and evaluation ofqualitybya European external quality assessment scheme. Virchows Arch 2011;459: 155-160.
14. Reimers MS, Zeestraten EC, Kuppen PJ et al. Biomarkers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf) 2013;1:166-183.
15. Xu Q, Xu AT, Zhu MM et al. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A meta-analysis. J Dig Dis 2013;14:409-416.
16. Guidelines and recommendations. Available at http://www.hgvs.org/content/guidelines. Accessed September 25, 2014.
17. Commission on Laboratory Accreditation. Laboratory Accreditation Program. Molecular pathology checklist. CAP 2014. College of American Pathologists.
18. ISO 15189:2012 Medical laboratories -Requirements for quality and competence. Geneva, Switzerland: International Organization for Standardization, 2012.
19. Coordination commission for the promotion ofquality assurance in laboratory research in health care. CCKL code of practice. Available at http://www.cckl.nl. Accessed September 25, 2014.
20. Lievre A. Des mutations de KRAS aux mutations de RAS: Vers une meilleure definition de la reponse aux anticorps anti-EGFR dans le cancer colorectal metastatique. Oncologie 2014;16:120 [in French].
21. 21. Tembuyser L, Ligtenberg MJ, Normanno N et al. Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer. J Mol Diagn 2014;16:371-377.
22. 22. Chen CC, Er TK, Liu YY et al. Computational analysis of KRAS mutations: Implications for different effects on the KRAS p.G12D and p.G13D mutations. PLoS One 2013;8:e55793.
23. Tejpar S, Celik I, Schlichting M et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012;30: 3570-3577.